Kazumasa Uemura (1), Shuko Yoshioka (1), Denise M. Surina-Baumgartner
(1), Tatsuo Tamagawa (1), Hisayuki Miura (2), Muneto Ueda (2), Norika Tamaya
(2), Akihisa Iguchi (2) and Nigishi Hotta (1)
(1) Third Department of Internal Medicine and (2) Department of Geriatric
Medicine, Nagoya University School of Medicine, 65 Tsuruma-cho, Showa-ku,
Nagoya 466-8550, Japan
Abstract: We investigated the effects of intracerebroventricular
administration of NIK-247 (9-amino-2,3,5,6,7,8-hexahydro-1H-cyclo-penta(b)-quinoline
monohydrate hydrochloride; a cholinesterase inhibitor) or MKC-231 (2-(2-oxypyrrolidin-1-yl)-N-
(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl) acetoamide; a
choline uptake enhancer) on plasma glucose level in comparison with that
of neostigmine administration in rats. The extents of NIK-247- and MKC-231-induced
hyperglycemia were considerably less than that by neostigmine, suggesting
that the potencies of the drugs to produce the peripheral hyperglycemia
may be pharmacologically negligible.
Keywords: NIK-247, MKC-231, Central hyperglycemia